1. Fibroblast growth factor 23 as a biomarker of right ventricular dysfunction in pulmonary hypertension
- Author
-
Laila Widmann, Stanislav Keranov, Leili Jafari, Christoph Liebetrau, Till Keller, Christian Troidl, Steffen Kriechbaum, Sandra Voss, Mani Arsalan, Manuel J. Richter, Khodr Tello, Henning Gall, Hossein A. Ghofrani, Stefan Guth, Werner Seeger, Christian W. Hamm, Oliver Dörr, and Holger Nef
- Subjects
General Medicine ,Cardiology and Cardiovascular Medicine - Abstract
Background Fibroblast growth factor 23 (FGF-23) has been associated with left ventricular hypertrophy (LVH) and heart failure. However, its role in right ventricular (RV) remodeling and RV failure is unknown. This study analyzed the utility of FGF-23 as a biomarker of RV function in patients with pulmonary hypertension (PH). Methods In this observational study, FGF-23 was measured in the plasma of patients with PH (n = 627), dilated cardiomyopathy (DCM, n = 59), or LVH with severe aortic stenosis (n = 35). Participants without LV or RV abnormalities served as controls (n = 36). Results Median FGF-23 plasma levels were higher in PH patients than in healthy controls (p p 2. Association of FGF-23 with parameters of RV function was independent of the glomerular filtration rate in regression analysis. Conclusion FGF-23 may serve as a biomarker for maladaptive RV remodeling in patients with PH. Graphic abstract
- Published
- 2023
- Full Text
- View/download PDF